Therapeutic Effects of Coenzyme Q10and Remacemide in Transgenic Mouse Models of Huntington's Disease

The Mouse Brain in Stereotaxic Coordinates

Paxinos, G. (2001) · Cited by 12,859

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes

MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366

mouse brain in stereotaxic coordinates

Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055

Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation

Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,188

Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid

Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., & Martin, J. B. (1986) · Nature · doi:10.1038/321168a0 · Cited by 1,287

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,060

Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid

Beal, M. F., Brouillet, E., Jenkins, B. G., Ferrante, R. J., Kowall, N. W., Miller, J., Storey, E., Srivastava, R., Rosen, B. R., & Hyman, B. T. (1993) · Journal of Neuroscience · doi:10.1523/jneurosci.13-10-04181.1993 · Cited by 1,026

Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia

Browne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885

Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images

Zhang, J., Peng, Q., Li, Q., Jahanshad, N., Hou, Z., Jiang, M., Masuda, N., Langbehn, D. R., Miller, M. I., Mori, S., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.10.027 · Cited by 94

Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease.

Chen, C. (2011) · PubMed · Cited by 89

Coenzyme Q10 ameliorates oxidative stress and prevents mitochondrial alteration in ischemic retinal injury

Lee, D.-W., Keun-young Kim, A., Shim, M. S., Kim, S. Y., Ellisman, M. H., Weinreb, R. N., & Ju, W. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0956-x · Cited by 89

Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots

Yang, S.-H., Li, W., Sumien, N., Forster, M. J., Simpkins, J. W., & Liu, R. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.005 · Cited by 89

Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice

Schilling, G., Savonenko, A. V., Coonfield, M. L., Morton, J. L., Vorovich, E. B., Gale, A., Neslon, C., Chan, N., Eaton, M., Fromholt, D., et al. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.01.003 · Cited by 85

Antioxidative defense mechanisms controlled by Nrf2: state-of-the-art and clinical perspectives in neurodegenerative diseases

Lim, J. L., Wilhelmus, M. M. M., de Vries, H. E., Drukarch, B., Hoozemans, J. J. M., & van Horssen, J. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1338-z · Cited by 84

Additive Neuroprotective Effects of Creatine and a Cyclooxygenase 2 Inhibitor Against Dopamine Depletion in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease

Klivènyi, P., Gardian, G., Calingasan, N. Y., Yang, L., & Beal, M. F. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:21:3:191 · Cited by 83

Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington’s disease

Rosas, H. D., Feigin, A., & Hersch, S. M. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.2.263 · Cited by 84

Mitochondrial medicine for neurodegenerative diseases

Du, H., & Yan, S. S. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.01.004 · Cited by 82

Animal models of Huntington's disease for translation to the clinic: Best practices

Menalled, L., & Brunner, D. (2014) · Movement Disorders · doi:10.1002/mds.26006 · Cited by 82

Neuroprotective Effects of Synaptic Modulation in Huntington's Disease R6/2 Mice

Stack, E. C., Dedeoglu, A., Smith, K. M., Cormier, K., Kubilus, J. K., Bogdanov, M. B., Matson, W. R., Yang, L., Jenkins, B. G., Luthi‐Carter, R., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4318-07.2007 · Cited by 80

Full Motor Recovery Despite Striatal Neuron Loss and Formation of Irreversible Amyloid-Like Inclusions in a Conditional Mouse Model of Huntington's Disease

Dı́az-Hernández, M., Torres-Peraza, J. F., Salvatori-Abarca, A., Morán, M. A., Gómez‐Ramos, P., Alberch, J., & Lucas, J. J. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3183-05.2005 · Cited by 80

A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules

Tanaka, M., Machida, Y., & Nukina, N. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0632-2 · Cited by 79

Improvement of Oxidative Stress and Mitochondrial Dysfunction by β-Caryophyllene: A Focus on the Nervous System

Ullah, H., Minno, A. D., Santarcangelo, C., Khan, H. Z., & Daglia, M. (2021) · Antioxidants · doi:10.3390/antiox10040546 · Cited by 81

PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease

Cherny, R. A., Ayton, S., Finkelstein, D. I., Bush, A. I., McColl, G., & Massa, S. M. (2012) · Journal of Huntington s Disease · doi:10.3233/jhd-120029 · Cited by 78

Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease.

Ryu, J. K., Choi, H. B., & McLarnon, J. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.05.043 · Cited by 83

Coenzyme Q treatment of neurodegenerative diseases of aging

Galpern, W. R., & Cudkowicz, M. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.01.004 · Cited by 78

Coenzyme Q10 a mitochondrial restorer for various brain disorders

Pradhan, N., Singh, C., & Singh, A. (2021) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-021-02161-8 · Cited by 79

Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection

Russo, R., Cavaliere, F., Rombolà, L., Gliozzi, M., Cerulli, A., Nucci, C., Fazzi, E. M., Bagetta, G., Corasaniti, M. T., & Morrone, L. A. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)01139-4 · Cited by 76

Redox Control of the Ubiquitin-Proteasome System: From Molecular Mechanisms to Functional Significance

Kriegenburg, F., Poulsen, E. G., Koch, A., Krüger, E., & Hartmann‐Petersen, R. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3590 · Cited by 77

Impaired Redox Signaling in Huntington’s Disease: Therapeutic Implications

Paul, B. D., & Snyder, S. H. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00068 · Cited by 76

Translating therapies for Huntington’s disease from genetic animal models to clinical trials

Hersch, S. M., & Ferrante, R. J. (2004) · NeuroRx · doi:10.1602/neurorx.1.3.298 · Cited by 75

Cystamine and cysteamine prevent 3‐NP‐induced mitochondrial depolarization of Huntington's disease knock‐in striatal cells

Mao, Z., Choo, Y. S., & Lesort, M. J. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04686.x · Cited by 75

Selenium reduction of ubiquinone via SQOR suppresses ferroptosis

Lee, N., Park, S. J., Lange, M., Tseyang, T., Doshi, M. B., Kim, T. Y., Song, Y., Kim, D. I., Greer, P. L., Olzmann, J. A., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-00974-4 · Cited by 76

NMDARs in neurological diseases: a potential therapeutic target

González, J., Jurado-Coronel, J. C., Ávila, M. F., Sabogal, A., Capani, F., & Barreto, G. E. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2014.940941 · Cited by 74

Coenzyme Q distribution in HL-60 human cells depends on the endomembrane system

Fernández‐Ayala, D. J. M., Brea‐Calvo, G., López‐Lluch, G., & Navas, P. (2005) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2005.05.010 · Cited by 74

Magnetic resonance imaging of Huntington's disease: preparing for clinical trials

Klöppel, S., Henley, S. M. D., Hobbs, N. Z., Wolf, R. C., Kassubek, J., Tabrizi, S. J., & Frackowiak, R. S. J. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.01.045 · Cited by 71

Role of Heat Shock Proteins During Polyglutamine Neurodegeneration: Mechanisms and Hypothesis

Wyttenbach, A. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:1-2:069 · Cited by 74

Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease

Sikorska, M., Lanthier, P., Miller, H., Beyers, M., Sodja, C., Zurakowski, B., Gangaraju, S., Pandey, S., & Sandhu, J. K. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.032 · Cited by 70

Comprehensive Behavioral Testing in the R6/2 Mouse Model of Huntington's Disease Shows No Benefit from CoQ10 or Minocycline

Menalled, L., Patry, M., Ragland, N., Lowden, P. A. S., Goodman, J., Minnich, J., Zahasky, B., Park, L., Leeds, J. M., Howland, D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009793 · Cited by 70

Use of magnetic resonance imaging for anatomical phenotyping of the R6/2 mouse model of Huntington's disease

Sawiak, S. J., Wood, N. I., Williams, G. B., Morton, A. J., & Carpenter, T. A. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.09.017 · Cited by 70

Detection of early behavioral markers of Huntington's disease in R6/2 mice employing an automated social home cage

Rudenko, O., Tkach, V., Berezin, V., & Bock, E. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.04.034 · Cited by 70

The therapeutic role of creatine in Huntington's disease

Ryu, H., Rosas, H. D., Hersch, S. M., & Ferrante, R. J. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.04.008 · Cited by 69

Clinical neuroprotection in Parkinson's disease — Still waiting for the breakthrough

Löhle, M., & Reichmann, H. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.025 · Cited by 70

The paradigm of Huntington’s disease: Therapeutic opportunities in neurodegeneration

Leegwater‐Kim, J., & Cha, J.-H. J. (2004) · NeuroRx · doi:10.1602/neurorx.1.1.128 · Cited by 68

Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease

Linares, G. R., Chiu, C., Scheuing, L., Leng, Y., Liao, H., Maric, D., & Chuang, D. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.04.003 · Cited by 69

Targeting CAG repeat RNAs reduces Huntington’s disease phenotype independently of huntingtin levels

Rué, L., Báñez-Coronel, M., Creus‐Muncunill, J., Giralt, A., Alcalá‐Vida, R., Mentxaka, G., Kagerbauer, B., Zomeño-Abellán, M. T., Aranda, Z., Venturi, V., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83185 · Cited by 67

Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3‐nitropropionic acid‐induced striatal damage

Fink, J. S., Kalda, A., Ryu, H., Stack, E. C., Schwarzschild, M. A., Chen, J., & Ferrante, R. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02145.x · Cited by 68

Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice

Li, M., Huang, Y., Ma, A. A. K., Lin, E., & Diamond, M. I. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.06.011 · Cited by 68

Coculture of Primary Motor Neurons and Schwann Cells as a Model for In Vitro Myelination

Hyung, S., Lee, B. Y., Park, J., Kim, J., Hur, E., & Suh, J. F. (2015) · Scientific Reports · doi:10.1038/srep15122 · Cited by 73

Protective Effects of Antioxidants in Huntington’s Disease: an Extensive Review

Essa, M. M., Moghadas, M., Ba-Omar, T., Qoronfleh, M. W., Guillemin, G. J., Manivasagam, T., Justin‐Thenmozhi, A., Ray, B., Bhat, A., Chidambaram, S. B., et al. (2019) · Neurotoxicity Research · doi:10.1007/s12640-018-9989-9 · Cited by 68

Magnetic resonance imaging and spectroscopy in assessing 3-nitropropionic acid-induced brain lesions: an animal model of Huntington’s disease

Lee, W., & Chang, C. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.02.002 · Cited by 67

Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines

Zádori, D., Klivènyi, P., Plangár, I., Toldi, J., & Vécsei, L. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01237.x · Cited by 68

Yeast Coq5 C-Methyltransferase Is Required for Stability of Other Polypeptides Involved in Coenzyme Q Biosynthesis

Baba, S. W., Belogrudov, G. I., Lee, J. C., Lee, P. T., Strahan, J. R., Shepherd, J. N., & Clarke, C. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313712200 · Cited by 65

The detection and measurement of locomotor deficits in a transgenic mouse model of Huntington's disease are task- and protocol-dependent: Influence of non-motor factors on locomotor function

Pallier, P. N., Drew, C. J. G., & Morton, A. J. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2008.10.007 · Cited by 64

Clinical trials of coenzyme Q10 in neurological disorders

Shults, C. W., & Haas, R. (2005) · BioFactors · doi:10.1002/biof.5520250113 · Cited by 62

The R6 lines of transgenic mice: A model for screening new therapies for Huntington's disease

Gil‐Mohapel, J., & Rego, A. C. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.001 · Cited by 67

Salidroside Protects Caenorhabditis elegans Neurons from Polyglutamine-Mediated Toxicity by Reducing Oxidative Stress

Xiao, L., Li, H., Zhang, J., Yang, F., Huang, A., Deng, J., Liang, M., Ma, F., Hu, M., & Huang, Z. (2014) · Molecules · doi:10.3390/molecules19067757 · Cited by 62

The role of immunity in Huntington's disease

Soulet, D., & Cicchetti, F. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.28 · Cited by 62

Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease

Klivènyi, P., Ferrante, R. J., Gardian, G., Browne, S. E., Chabrier, P., & Beal, M. F. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.t01-1-01868.x · Cited by 62

Functional Characterization of OsPPT1, Which Encodes p-Hydroxybenzoate Polyprenyltransferase Involved in Ubiquinone Biosynthesis in Oryza sativa

Ohara, K., Yamamoto, K., Hamamoto, M., Sasaki, K., & Yazaki, K. (2006) · Plant and Cell Physiology · doi:10.1093/pcp/pcj025 · Cited by 62

Huntington's disease: An update of therapeutic strategies

Kumar, A., Singh, S. K., Kumar, V., Kumar, D., Agarwal, S., & Rana, M. K. (2014) · Gene · doi:10.1016/j.gene.2014.11.022 · Cited by 62

Engineering of ubiquinone biosynthesis using the yeast coq2 gene confers oxidative stress tolerance in transgenic tobacco

Ohara, K., Kokado, Y., Yamamoto, H., Sato, F., & Yazaki, K. (2004) · The Plant Journal · doi:10.1111/j.1365-313x.2004.02246.x · Cited by 64

Coenzyme Q10 effects in neurological diseases

Rauchová, H. (2021) · Physiological Research · doi:10.33549/physiolres.934712 · Cited by 68

Effects of Coenzyme Q10 in Huntington's disease and early Parkinson's disease

Beal, M. F., & Shults, C. W. (2003) · BioFactors · doi:10.1002/biof.5520180218 · Cited by 60

Integrating fetal neural transplants into a therapeutic strategy: the example of Huntington's disease

Peschanski, M. (2004) · Brain · doi:10.1093/brain/awh145 · Cited by 57

Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease

Ramaswamy, S., McBride, J. L., Han, I., Berry‐Kravis, E., Zhou, L., Herzog, C. D., Gasmi, M., Bartus, R. T., & Kordower, J. H. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.12.005 · Cited by 57

Characterization of in vivo anti-rotavirus activities of saponin extracts from Quillaja saponaria Molina

Tam, K. I., & Roner, M. R. (2011) · Antiviral Research · doi:10.1016/j.antiviral.2011.04.004 · Cited by 56

The Neuroprotective Role of Creatine

Klein, A., & Ferrante, R. J. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6486-9_11 · Cited by 56

Therapeutic Effects of Coenzyme Q10 in Neurodegenerative Diseases

Beal, M. F. (2004) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)82026-3 · Cited by 55

Transgenic mouse models of neurodegenerative disease: Opportunities for therapeutic development

Jankowsky, J. L., Savonenko, A. V., Schilling, G., Wang, J., Xu, G. M., & Borchelt, D. (2002) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-002-0073-7 · Cited by 57

Redox Signaling Pathways Involved in Neuronal Ischemic Preconditioning

Thompson, J. W., Narayanan, S., & Pérez‐Pinzón, M. A. (2012) · Current Neuropharmacology · doi:10.2174/157015912804143577 · Cited by 55

Lipophilic antioxidants in neurodegenerative diseases

Chang, K., Cheng, M., Chiang, M.-C., & Chen, C. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.06.031 · Cited by 59

Mitochondrial Membrane Fluidity is Consistently Increased in Different Models of Huntington Disease: Restorative Effects of Olesoxime

Eckmann, J., Clemens, L. E., Eckert, S. H., Hagl, S., Yu-Taeger, L., Bordet, T., Pruss, R. M., Muller, W. E., Leuner, K., Nguyen, H. P., et al. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8663-3 · Cited by 56

Exploratory Activity and Fear Conditioning Abnormalities Develop Early in R6/2 Huntington's Disease Transgenic Mice.

Bolivar, V. J., MANLEY, K. M., & Messer, A. C. (2003) · Behavioral Neuroscience · doi:10.1037/0735-7044.117.6.1233 · Cited by 54

Manganese and the Insulin-IGF Signaling Network in Huntington’s Disease and Other Neurodegenerative Disorders

Bryan, M. R., & Bowman, A. B. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-60189-2_6 · Cited by 56

Huntington’s Disease

Roze, E. F., Bonnet, C., Bétuing, S., & Caboche, J. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6448-9_5 · Cited by 54

Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the R6/2 Mouse Model of HD

Rattray, I., Smith, E. J., Gale, R., Matsumoto, K., Bates, G. P., & Modo, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060012 · Cited by 52

Potential Future Neuroprotective Therapies for Neurodegenerative Disorders and Stroke

Tarawneh, R. M., & Galvin, J. E. (2010) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.12.003 · Cited by 54

Oxidative stress is increased in C. elegans models of Huntington’s disease but does not contribute to polyglutamine toxicity phenotypes

Machiela, E., Dues, D. J., Senchuk, M. M., & Raamsdonk, J. M. V. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.08.008 · Cited by 53

Dysregulation of PGC-1α-Dependent Transcriptional Programs in Neurological and Developmental Disorders: Therapeutic Challenges and Opportunities

McMeekin, L. J., Fox, S. N., Boas, S. M., & Cowell, R. M. (2021) · Cells · doi:10.3390/cells10020352 · Cited by 53

Protective Effects of Coenzyme Q10 Against Hydrogen Peroxide-Induced Oxidative Stress in PC12 Cell: The Role of Nrf2 and Antioxidant Enzymes

Li, L., Du, J., Lian, Y., Zhang, Y. L., Li, X., Liu, Y., Zou, L., & Wu, T. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0224-4 · Cited by 51

Experimental therapeutics in Huntington's disease

Bates, G. P., & Hockly, E. (2003) · Current Opinion in Neurology · doi:10.1097/01.wco.0000084223.82329.bb · Cited by 51

Pathogenic Mechanisms in Huntington's Disease

Jones, L., & Hughes, A. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-381328-2.00015-8 · Cited by 51

Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model

Cheng, Y., Peng, Q., Hou, Z., Aggarwal, M., Zhang, J., Mori, S., Ross, C. A., & Duan, W. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.02.022 · Cited by 50

Recent advances in Huntingtonʼs disease: implications for experimental therapeutics

Feigin, A., & Zgaljardic, D. J. (2002) · Current Opinion in Neurology · doi:10.1097/00019052-200208000-00013 · Cited by 50

The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start?☆

Lee, J.-H., Boo, J. H., & Ryu, H. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.07.016 · Cited by 51

Behavioral Improvement after Chronic Administration of Coenzyme Q10 in P301S Transgenic Mice

Elipenahli, C., Stack, C., Jainuddin, S., Gerges, M., Yang, L., Starkov, A. A., Beal, M. F., & Dumont, M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111190 · Cited by 49

A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease

Mievis, S., Blum, D. L., & Ledent, C. A. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.09.021 · Cited by 48

Reactive Species in Huntington Disease: Are They Really the Radicals You Want to Catch?

Bono-Yagüe, J., Gómez-Escribano, A. P., Millán, J. M., & Vázquez‐Manrique, R. P. (2020) · Antioxidants · doi:10.3390/antiox9070577 · Cited by 52

Kennedy's disease: pathogenesis and clinical approaches

Greenland, K. J., & Zajac, J. D. (2004) · Internal Medicine Journal · doi:10.1111/j.1444-0903.2004.00588.x · Cited by 48

Mitochondrial nuclear receptors and transcription factors: Who's minding the cell?

Lee, J.-H., Sharma, S., Kim, J., Ferrante, R. J., & Ryu, H. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21564 · Cited by 48

Coenzyme Q10 Supplementation Reverses Age-Related Impairments in Spatial Learning and Lowers Protein Oxidation

Shetty, R. A., Forster, M. J., & Sumien, N. (2013) · AGE · doi:10.1007/s11357-012-9484-9 · Cited by 47

Biotin, coenzyme Q10, and their combination ameliorate aluminium chloride‐induced Alzheimer's disease via attenuating neuroinflammation and improving brain insulin signaling

Attia, H., Albuhayri, S., Alaraidh, S., Alotaibi, A., Yacoub, H. I., Mohamad, R. A., & Alamin, M. A. (2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22519 · Cited by 47

A small molecule p75NTRligand normalizes signalling and reduces Huntington’s disease phenotypes in R6/2 and BACHD mice

Simmons, D. A., Belichenko, N. P., Ford, E. C., Semaan, S., Monbureau, M., Aiyaswamy, S., Holman, C. M., Condon, C., Shamloo, M., Massa, S. M., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw316 · Cited by 46

Reduced Coenzyme Q10 Supplementation Decelerates Senescence in SAMP1 Mice

Yan, J., Fujii, K., Yao, J., Kishida, H., Hosoe, K., Sawashita, J., Takeda, T., Mori, M., & Higuchi, K. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2005.11.007 · Cited by 45

Role of Mitochondrial Dysfunctions in Neurodegenerative Disorders: Advances in Mitochondrial Biology

Kathiresan, D. S., Balasubramani, R., Marudhachalam, K., Jaiswal, P., Ramesh, N., Suruthi, G. S., Moorthi, P. V., & Vijayan, M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04469-x · Cited by 49

Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease

Vámos, E., Vörös, K., Vécsei, L., & Klivènyi, P. (2009) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2009.06.020 · Cited by 45

Neuroprotection for Huntington’s Disease: Ready, Set, Slow

Hersch, S. M., & Rosas, H. D. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.01.003 · Cited by 44

Mitochondrial matters of the brain: the role in Huntington’s disease

Turner, C., & Schapira, A. H. V. (2010) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-010-9290-y · Cited by 45

Spinocerebellar ataxias caused by polyglutamine expansions: A review of therapeutic strategies

Underwood, B. R., & Rubinsztein, D. C. (2008) · The Cerebellum · doi:10.1007/s12311-008-0026-z · Cited by 44

Caudate volume as an outcome measure in clinical trials for Huntington’s disease: a pilot study

Aylward, E., Rosenblatt, A., Field, K., Yallapragada, V., Kieburtz, K. D., McDermott, M., Raymond, L. A., Almqvist, E. W., Hayden, M. R., & Ross, C. A. (2003) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2003.09.005 · Cited by 41

Targeting cellular energy production in neurological disorders

Baker, S. K., & Tarnopolsky, M. A. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.10.1655 · Cited by 43

Cell Rearrangement and Oxidant/Antioxidant Imbalance in Huntington’s Disease

D’Egidio, F., Castelli, V., Cimini, A., & d’Angelo, M. (2023) · Antioxidants · doi:10.3390/antiox12030571 · Cited by 42

Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice

Norflus, F., Nanje, A., Gutekunst, C., Shi, G.-M., Cohen, J. A., Bejarano, M., Fox, J. H., Ferrante, R. J., & Hersch, S. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.011 · Cited by 42

Coenzyme Q10 protects SHSY5Y neuronal cells from beta amyloid toxicity and oxygen‐glucose deprivation by inhibiting the opening of the mitochondrial permeability transition pore

Li, G., Zou, L., Cao, C., & Yang, E. S. (2005) · BioFactors · doi:10.1002/biof.5520250111 · Cited by 41

Striatal Expression of a Calmodulin Fragment Improved Motor Function, Weight Loss, and Neuropathology in the R6/2 Mouse Model of Huntington's Disease

Dai, Y., Dudek, N. L., Li, Q., Fowler, S. C., & Muma, N. A. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.3307-09.2009 · Cited by 41

Ubiquilin-1 Overexpression Increases the Lifespan and Delays Accumulation of Huntingtin Aggregates in the R6/2 Mouse Model of Huntington's Disease

Safren, N., Ayadi, A. E., Chang, L., Terrillion, C. E., Gould, T. D., Boehning, D. F., & Monteiro, M. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087513 · Cited by 40

Coenzyme Q protects Caenorhabditis elegans GABA neurons from calcium-dependent degeneration

Earls, L. R., Hacker, M. L., Watson, J. D., & Miller, D. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910630107 · Cited by 39

Cause or compensation?—Altered neuronal Ca2+ handling in Huntington's disease

Mackay, J. P., Nassrallah, W. B., & Raymond, L. A. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12817 · Cited by 40

Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model

Schilling, G., Coonfield, M. L., Ross, C. A., & Borchelt, D. R. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02326-6 · Cited by 151

Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice

Smith, K. M., Matson, S., Matson, W. R., Cormier, K., Del Signore, S. J., Hagerty, S. W., Stack, E. C., Ryu, H., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.03.004 · Cited by 127

A randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s disease

The Huntington Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.397 · Cited by 312

Targeting energy metabolism in Huntington's disease

Walker, F. O., & Raymond, L. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16739-1 · Cited by 21

Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice

Stack, E. C., Smith, K. M., Ryu, H., Cormier, K., Chen, M., Hagerty, S. W., Del Signore, S. J., Cudkowicz, M. E., Friedlander, R. M., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.11.002 · Cited by 114